E P Alyea

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation
    E Alyea
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 8:139-44. 2002
  2. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
  3. pmc Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:4586-8. 2007
  4. ncbi request reprint Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
    E P Alyea
    Divisions of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 91:3671-80. 1998
  5. ncbi request reprint CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study
    E P Alyea
    Center for Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:123-8. 2004
  6. ncbi request reprint Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
    E Alyea
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, MA 02215, USA
    Bone Marrow Transplant 32:1145-51. 2003
  7. ncbi request reprint Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1047-55. 2006
  8. doi request reprint Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect
    Edwin P Alyea
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 01770, USA
    Best Pract Res Clin Haematol 21:239-50. 2008
  9. pmc Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Edwin P Alyea
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:920-6. 2008
  10. pmc NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignan
    Edwin P Alyea
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:1037-69. 2010

Collaborators

Detail Information

Publications70

  1. ncbi request reprint Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation
    E Alyea
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 8:139-44. 2002
    ..Future efforts to reduce the risk of relapse after TCD BMT should focus on immunologic methods to induce the graft-versus-leukemia effect after BMT rather than intensification of the ablative regimen by escalation of irradiation dose...
  2. ncbi request reprint Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1056-64. 2006
    ....
  3. pmc Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:4586-8. 2007
    ..They also suggest future prospective trials to examine the potential benefit of chelation therapy in this setting...
  4. ncbi request reprint Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
    E P Alyea
    Divisions of Hematologic Malignancies and Biostatistics, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 91:3671-80. 1998
    ....
  5. ncbi request reprint CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study
    E P Alyea
    Center for Hematologic Oncology, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:123-8. 2004
    ..The CD8-HDM Cell Separation System appears to be highly selective and effective in depleting CD8+ T cells from DLI apheresis products, and CD8-depleted DLI is capable of mediating a graft-versus-leukemia effect while minimizing GVHD...
  6. ncbi request reprint Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect
    E Alyea
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, MA 02215, USA
    Bone Marrow Transplant 32:1145-51. 2003
    ..Strategies focused on reducing nonrelapse mortality in allogeneic transplantation may translate into an improved outcome for patients receiving allogeneic transplantation...
  7. ncbi request reprint Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 12:1047-55. 2006
    ..These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation...
  8. doi request reprint Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect
    Edwin P Alyea
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 01770, USA
    Best Pract Res Clin Haematol 21:239-50. 2008
    ..Laboratory efforts to identify the targets of GVHD and GVL may allow for more specific and effective therapies to be developed while minimizing toxicity...
  9. pmc Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Edwin P Alyea
    Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:920-6. 2008
    ....
  10. pmc NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignan
    Edwin P Alyea
    Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:1037-69. 2010
    ....
  11. ncbi request reprint Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation
    Edwin P Alyea
    Biol Blood Marrow Transplant 8:601-7. 2002
    ..However, these adverse events do not lead to inferior probability of relapse-free survival because they are accompanied by a reduction in relapse rates...
  12. ncbi request reprint T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect
    E Alyea
    Center for Hematologic Oncology and Department of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 98:934-9. 2001
    ..Therefore, less toxic transplantation strategies are needed to allow a higher proportion of patients to receive DLI and the benefit from the GVM effect after transplantation. (Blood. 2001;98:934-939)..
  13. ncbi request reprint Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age
    Edwin P Alyea
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Blood 105:1810-4. 2005
    ..052). Our experience suggests that, in patients over age 50, NST with fludarabine and low-dose busulfan leads to an overall outcome at least as good as that following myeloablative therapy...
  14. ncbi request reprint HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation
    V T Ho
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 37:845-50. 2006
    ..0001). Cumulative relapse incidence was 35% in the HLA-C-mismatched and 55% in the 10/10-matched cohort, P=0.09. HLA-C mismatch is associated with inferior survival after URD NST...
  15. ncbi request reprint CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors
    R J Soiffer
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1152-9. 2001
    ..Herein, we report results in the first 48 recipients of unrelated marrow using CD6+ TCD as the sole form of GVHD prophylaxis...
  16. pmc (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma
    K E Abou-Nassar
    Lymphoma Program, Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115 6084, USA
    Bone Marrow Transplant 46:1503-9. 2011
    ..Two-year OS and PFS were 83% (±11%) and 74% (±13%), respectively. This treatment is associated with favorable outcomes including acceptable rates of GVHD and relapse in advanced FL patients, and warrants prospective studies...
  17. pmc A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome
    E D Jacobsen
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Ann Oncol 22:1608-13. 2011
    ..The prognosis for patients with most forms of T-cell lymphoma is poor. Allogeneic hematopoietic stem-cell transplantation (HSCT) may improve the outcome...
  18. ncbi request reprint Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy
    A M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 40:209-17. 2007
    ..Our data suggest that substantially lower costs and fewer days of hospitalization within the first year after RICT procedures can be obtained with no compromise of long-term clinical outcomes compared to HDCT procedures...
  19. ncbi request reprint Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults
    E P Hochberg
    Disease Center for Hematologic Oncology, Department of Adult Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston MA 02115, USA
    Blood 98:1116-21. 2001
    ..These studies demonstrate that T-cell neogenesis contributes to immune reconstitution in adult patients and suggest that thymic function can be manipulated in vivo. (Blood. 2001;98:1116-1121)..
  20. pmc Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome
    J R Brown
    Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Leukemia 27:362-9. 2013
    ..0001). We conclude that RIC HSCT for CLL in the current era is associated with excellent long-term PFS and OS, and, as potentially curative therapy, should be considered early in the disease course of relapsed high-risk CLL patients...
  21. ncbi request reprint Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation
    V T Ho
    Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 7:223-9. 2001
    ..Patients with pretransplantation FEV1 of < or = 80% appear to have a higher risk for SPCs...
  22. pmc CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia
    X F Yang
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 98:7492-7. 2001
    ..These findings suggest that CML66 may be immunogenic in a wide variety of malignancies and may be a target for antigen-specific immunotherapy...
  23. ncbi request reprint Quality of life associated with acute and chronic graft-versus-host disease
    S J Lee
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Bone Marrow Transplant 38:305-10. 2006
    ..The adverse effects of acute GVHD are detectable with the TOI at 6 months post transplantation after which development of chronic GVHD is the most strongly correlated with worse QOL...
  24. ncbi request reprint Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease
    V T Ho
    Department of Medical Oncology, Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 34:987-94. 2004
    ..There was no correlation between CD8+ number and GVHD or survival. A 2-log depletion of CD8+ cells from PBSC is insufficient to prevent GVHD...
  25. ncbi request reprint A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells
    E Zorn
    Center for Hematologic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women Hospital, Harvard Medical School, Boston, MA 02115, USA
    Transplantation 71:1131-7. 2001
    ..Based on these findings, CD4+ T cells with BCR-ABL specificity do not appear to be mediators of the anti-leukemia response in vivo after donor lymphocyte infusion...
  26. ncbi request reprint Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
    Joseph H Antin
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1601-5. 2003
    ..This novel agent is worthy of further study in allogeneic transplantation...
  27. pmc Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy
    P Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Bone Marrow Transplant 45:1611-7. 2010
    ..A significant proportion of women with tAML/MDS after breast cancer treatment experience DFS after HSCT, similar to that of patients with de novo MDS or AML. This justifies consideration of HSCT for selected patients in this setting...
  28. pmc Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning
    Philippe Armand
    Departments of Medical Oncology and Biostatistics, Dana Farber Cancer Institute, Boston 02115, USA
    J Clin Oncol 26:5767-74. 2008
    ..We hypothesized that the use of sirolimus for GVHD prophylaxis in patients with lymphoma might lead to improved survival after transplantation through a decreased incidence of disease progression...
  29. pmc Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 114:3956-9. 2009
    ..Bortezomib is a promising novel immunomodulatory agent in allogeneic transplantation. This study was registered at http://www.clinicaltrials.gov as #NCT00369226...
  30. pmc Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia
    C J Wu
    Center for Hematologic Oncology, and Department of Biostatistical Science, Dana Farber Cancer Institute, and Department of Medicine, and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 106:705-14. 2000
    ..The characterization of B cell-defined antigens may help identify clinically relevant targets of the GVL response in vivo...
  31. ncbi request reprint Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
    Martha Wadleigh
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 102:1578-82. 2003
    ..Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD...
  32. pmc Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:655-64. 2007
    ....
  33. pmc Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation
    R L Haspel
    Department of Pathology, Beth Israel Deaconess Medical Centre, Boston, MA 02115, USA
    Bone Marrow Transplant 41:523-9. 2008
    ....
  34. ncbi request reprint Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
    Roberto Bellucci
    Center for Hematologic Oncology and Department of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Blood 99:4610-7. 2002
    ..05). These results provide evidence that prophylactic infusion of CD4(+) donor lymphocytes 6 months after BMT enhances reconstitution of donor T cells and conversion to donor hematopoiesis as well as promoting antitumor immunity...
  35. ncbi request reprint Routine screening for psychosocial distress following hematopoietic stem cell transplantation
    S J Lee
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Bone Marrow Transplant 35:77-83. 2005
    ..Pre-transplant distress appears to be highly predictive of distress post transplant and is a feasible marker to target screening and intervention programs...
  36. pmc Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis
    Francisco M Marty
    Division of Infectious Diseases, Boston, MA 02115, USA
    Blood 110:490-500. 2007
    ..66; P = .14 and P = .35, respectively). The protective effect of sirolimus-containing GVHD prophylaxis regimens on CMV reactivation should be confirmed in randomized trials...
  37. ncbi request reprint Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells
    Emmanuel Zorn
    Center for Hematologic Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 8:2052-60. 2002
    ..In this situation however, the immune effector cells responsible for tumor rejection have not been identified. The goal of this study was to characterize these effector populations...
  38. pmc Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation
    Ken Ichi Matsuoka
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 120:1479-93. 2010
    ..These studies indicate that CD4+ lymphopenia is a critical factor in Treg homeostasis and that prolonged imbalance of Treg homeostasis after HSCT can result in loss of tolerance and significant clinical disease manifestations...
  39. ncbi request reprint Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Vincent T Ho
    Dana Farber Cancer Institute, 44 Binney St, D1B21, Boston, MA 02115, USA
    Blood 104:1224-6. 2004
    ..Eight of 24 patients (33%) are alive at 6.3 to 24.6 months (median, 7.2 months). Denileukin diftitox is tolerable and has promising activity in steroid-refractory acute GVHD...
  40. pmc Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission
    David B Miklos
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
    Blood 105:2973-8. 2005
    ..Antibody response to Y-chromosome encoded histocompatibility antigens (H-Y antigens) was also associated with maintenance of disease remission (P < .0001). B cells may provide a new target for immune intervention in chronic GVHD...
  41. ncbi request reprint The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha
    R Salgia
    Department of Medical Oncology, Division of Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 94:4233-46. 1999
    ....
  42. pmc Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:418-25. 2008
    ..These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population...
  43. ncbi request reprint Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs
    Stephanie J Lee
    Department of Adult Oncology and Department of Biostatistical Science, Dana Farber Cancer Institute, and the Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Blood 100:2697-702. 2002
    ..As prospective, randomized studies comparing methods of GVHD prophylaxis are performed, assessment of quality of life and costs should be included to fully understand the overall impact of each intervention...
  44. pmc Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease
    Stefanie Sarantopoulos
    Division of Hematologic Malignancies and Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 113:3865-74. 2009
    ..These studies delineate specific abnormalities of B-cell homeostasis in patients with cGVHD and suggest that BAFF targeting agents may be useful in this disease...
  45. pmc Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation
    Vincent T Ho
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Biol Blood Marrow Transplant 15:844-50. 2009
    ..The omission of mini-MTX from the Tac/Sir GVHD prophylaxis regimen appears to have no adverse effect on the development of aGVHD...
  46. ncbi request reprint Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation
    Thomas S Lin
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Transplantation 74:49-54. 2002
    ..We sought to determine the effect of prior donor and patient CMV exposure on the incidence of CMV infection after TCD allogeneic HSCT...
  47. pmc Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 16:792-800. 2010
    ..62, P = .03) associated with poorer PFS. RIC HSCT is well tolerated, with reasonable survival in elderly patients. Age is not associated with impaired outcomes. HSCT should not be excluded solely based on advanced patient age...
  48. pmc Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease
    Emmanuel Zorn
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 106:2903-11. 2005
    ..These findings support the development of new strategies to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to prevent or correct cGVHD...
  49. doi request reprint Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 17:421-8. 2011
    ..In summary, we document a high incidence of ES after syngeneic HSCT. The trend of increased NRM after ES requires reevaluation in a larger syngeneic HSCT cohort...
  50. pmc Costs of allogeneic hematopoietic cell transplantation with high-dose regimens
    Akiko M Saito
    Division of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 14:197-207. 2008
    ..If no complications occurred, the mean cost within the first year was $79,222. These results provide cost estimates for complicated and uncomplicated HDCT procedures, as well as costs for management of specific transplant complications...
  51. pmc A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation
    Philippe Armand
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 14:28-35. 2008
    ....
  52. ncbi request reprint Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion
    Robert J Soiffer
    Biol Blood Marrow Transplant 8:625-32. 2002
    ..Our results indicate that CD8 depletion reduces the incidence of GVHD associated with DLI without adversely affecting conversion to donor hematopoiesis or immunologic recovery...
  53. ncbi request reprint Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
    Stephanie J Lee
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 104:1559-64. 2004
    ..002). Both relapse- and GVHD-related mortality contributed to the increased mortality in the combination group. The combination of corticosteroids and daclizumab should not be used as initial therapy of acute GVHD...
  54. ncbi request reprint Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study
    Francisco M Marty
    Division of Infectious Diseases and Hematopoietic Stem Cell Transpalntation Service, Brigham and Women s Hospital and Dana Farber Cancer Instiute, Harvard Medical School, Boston, MA 02115, USA
    Blood 102:2768-76. 2003
    ..Pre-emptive systemic antifungal therapy against molds should be considered in patients who develop severe GVHD after HSCT if infliximab is used...
  55. ncbi request reprint High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 13:183-96. 2007
    ..01; 95% confidence interval, 1.64-5.50). Hence, evaluating alternative therapeutic options upfront may also be reasonable...
  56. ncbi request reprint Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens
    Roberto Bellucci
    Dana Farber Cancer Institute, M530, 44 Binney St, Boston, MA 02115, USA
    Blood 103:656-63. 2004
    ..The expression of these genes was evaluated in primary myeloma cells and in normal plasma cells. This study demonstrates that the GVM response is associated with antibody responses to highly expressed myeloma-associated antigens...
  57. pmc Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion
    Wandi Zhang
    Cancer Vaccine Center and Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Skin Disease Research Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 16:2729-39. 2010
    ..The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized...
  58. pmc Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia
    John G Gribben
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
    Blood 106:4389-96. 2005
    ..From these findings we have altered our approach for patients with high-risk CLL and are currently exploring the role of related and unrelated allogeneic SCT following reduced-intensity conditioning regimens...
  59. ncbi request reprint Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease
    Daniel J DeAngelo
    Dana Farber Cancer Institute, Department of Adult Oncology, Boston, Massachusetts 02115, USA
    Clin Cancer Res 10:5065-71. 2004
    ..Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses...
  60. ncbi request reprint Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion
    Enrica Orsini
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 63:2561-8. 2003
    ..In contrast, T-cell clones associated with GVHD are expanded de novo after DLI...
  61. ncbi request reprint A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation
    Ephraim P Hochberg
    Center for Hematologic Oncology and the Department of Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 101:363-9. 2003
    ..SNP-based assessment of chimerism is a promising technique that will assist in the analysis of outcomes following transplantation...
  62. pmc Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor
    Roberto Bellucci
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, M530, Boston, MA 02115, USA
    Blood 105:3945-50. 2005
    ..These results demonstrate that BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo...
  63. pmc Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review
    John Koreth
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Boston, Massachustts, USA
    Biol Blood Marrow Transplant 15:1502-12. 2009
    ....
  64. ncbi request reprint Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy
    Abba C Zubair
    Connell O Reilly Cell Manipulation Core Facility, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Transfusion 44:253-61. 2004
  65. pmc Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation
    Emmanuel Zorn
    Division of Hematologic Malignancies, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 15:382-8. 2009
    ..This study suggests that administration of low-dose IL-2 combined with adoptive CD4(+) cellular therapy may provide a mechanism to expand Treg in vivo...
  66. pmc Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis
    Roberto Bellucci
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 109:2001-7. 2007
    ..Interestingly, the epitope specificity of these PDC-E2 autoantibodies was distinctive, suggesting that the mechanisms leading to loss of tolerance in the transplantation patients are distinct from PBC...
  67. ncbi request reprint CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells
    Xiao Feng Yang
    Center for Hematologic Oncology, Dana Farber Cancer Institute, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer Res 62:5517-22. 2002
    ..Moreover, given its expression and immunogenicity in a wide variety of malignancies, CML28 merits additional evaluation as a target for antigen-specific immunotherapy...
  68. ncbi request reprint Donor lymphocyte infusions
    Vincent T Ho
    Bone Marrow Transplant Program, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Adv Pharmacol 51:319-45. 2004
  69. pmc Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells
    Melinda A Biernacki
    Cancer Vaccine Center and Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 70:906-15. 2010
    ....
  70. pmc Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens
    Ovidiu Marina
    Cancer Vaccine Center and Departments of Medical Oncology and Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Res 70:1344-55. 2010
    ..Moreover, antibody reactivity against these antigens was temporally correlated with clinical disease regression. These B-cell antigens represent promising biomarkers of effective anti-CLL immunity...